Catalyst
Slingshot members are tracking this event:
Mallinckrodt to complete Phase 4 study of Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients in Q1 2017
- Source Link:
- https://clinicaltrials.gov/ct2/show/NCT01386554
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
MNK |
|
|
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 03, 2017
Occurred Source:
https://clinicaltrials.gov/ct2/show/NCT01386554
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 4, Acthar, Repository Corticotropin Injection, Proteinuria, Nephropathy, Placebo-controlled, Double Blind